Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
Authors:
- David A. PalmaDPDavid A. Palma
- Robert OlsonRobert Olson
- Stephen HarrowSHStephen Harrow
- Stewart GaedeSGStewart Gaede
- Alexander V. LouieALAlexander V. Louie
- Cornelis HaasbeekCHCornelis Haasbeek
- Liam MulroyLMLiam Mulroy
- Michael LockMichael Lock
- George B. RodriguesGRGeorge B. Rodrigues
- Brian P. YaremkoBYBrian P. Yaremko
- Devin SchellenbergDSDevin Schellenberg
- Belal AhmadBABelal Ahmad
Preprint
Abstract
Purpose: The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. Methods: We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial. Results: Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms. Conclusions: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. ( NCT01446744 ) Funding: Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst GrantKeywords
All Related Versions
- Published version: Journal of Clinical Oncology, 38 (25), 2830.
This publication has 24 references indexed in Scilit:
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell, 2018
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017
- Stereotactic Body Radiotherapy for OligometastasisThe Cancer Journal, 2016
- The rise in metastasectomy across cancer types over the past decadeCancer, 2014
- The oligometastatic state—separating truth from wishful thinkingNature Reviews Clinical Oncology, 2014
- Tracking the clonal origin of lethal prostate cancerJournal of Clinical Investigation, 2013
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- A survey of stereotactic body radiotherapy use in the United StatesCancer, 2011
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and LobectomyJournal of Urology, 1939